-
公开(公告)号：US12098371B2
公开(公告)日：2024-09-24
申请号：US18451013
申请日：2023-08-16
发明人： Mufa Zou , David Yu , Aldrich N. K. Lau , Ruiming Zou , Wing C. Poon , Gang Zhao , Gengyu Du , Yun-Chiao Yao , Allen Wong , Xiaojun Li
IPC分类号： C12N15/117 , B01J19/00
CPC分类号： C12N15/117 , B01J19/0046 , C12N2310/14 , C12N2310/17 , C12N2310/3515
摘要： Embodiments of the present disclosure relate to lipid-PEGylated solid support and phosphoramidites derivatives, methods for preparing the same, and their uses in the delivery of oligonucleotide drugs to the cellular targets.
-
公开(公告)号：US12098369B2
公开(公告)日：2024-09-24
申请号：US18075085
申请日：2022-12-05
发明人： Nikhil Dhar , Marianna Keaveney , Kyle Backman , Everett Webster , Nikolai Eroshenko , Justin Quinn
IPC分类号： C07H21/04 , C12N15/113 , C12N15/117
CPC分类号： C12N15/113 , C12N15/117 , C12N2310/141 , C12N2310/334 , C12N2310/335
摘要： Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.
-
公开(公告)号：US12029760B2
公开(公告)日：2024-07-09
申请号：US16609628
申请日：2018-05-02
发明人： Yangbing Zhao , Jiangtao Ren
IPC分类号： A61K35/17 , C12N9/22 , C12N15/10 , C12N15/117 , C12N15/90 , A61K39/00 , A61P35/00 , A61P37/02
CPC分类号： A61K35/17 , C12N9/22 , C12N15/102 , C12N15/117 , C12N15/90 , A61K2039/5158 , A61P35/00 , A61P37/02 , C12N2310/122 , C12N2310/20 , C12N2310/315
摘要： The present invention includes compositions and methods for modifying primary T cells. In one aspect, the invention comprises administering to a cell a stem-loop Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (st-crRNA) and a Cpf1 enzyme.
-
公开(公告)号：US20240158802A1
公开(公告)日：2024-05-16
申请号：US18520449
申请日：2023-11-27
发明人： Samuel DEUTSCH , Daniel FRIMANNSSON , Nicole FAY , Colin McKINLAY , Ole HAABETH
IPC分类号： C12N15/117 , A61K9/14 , A61K45/06 , A61P35/00 , C07K16/28
CPC分类号： C12N15/117 , A61K9/145 , A61K45/06 , A61P35/00 , C07K16/2818
摘要： Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.
-
公开(公告)号：US20240158801A1
公开(公告)日：2024-05-16
申请号：US18393461
申请日：2023-12-21
申请人： UNIVERSITY OF MIAMI
发明人： Glen N Barber
IPC分类号： C12N15/117 , A61K9/127 , A61K31/713 , A61K39/00 , A61K39/39 , A61P35/00 , B82Y5/00 , C12N5/0784 , C12N15/88
CPC分类号： C12N15/117 , A61K9/127 , A61K31/713 , A61K39/0011 , A61K39/39 , A61K39/4615 , A61K39/4622 , A61K39/464499 , A61P35/00 , B82Y5/00 , C12N5/0639 , C12N15/88 , A61K2039/5152 , A61K2039/55561 , A61K2039/585 , C12N2501/2301 , C12N2501/25 , C12N2502/30 , C12N2502/99
摘要： Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) can be delivered to antigen presenting cells. In various embodiments of the present invention, the STAVs can be delivered in lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers Nano-STAVs into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity. The STAV formulations can be introduced into solid tumors present in the mammal. Alternatively, the Nano-STAVs can be introduced through direct inoculation. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.
-
公开(公告)号：US20240131194A1
公开(公告)日：2024-04-25
申请号：US18471738
申请日：2023-09-20
发明人： Katalin Kariko , Drew Weissman
IPC分类号： A61K48/00 , A61K38/17 , A61K38/18 , A61K38/50 , C07H21/02 , C07K14/47 , C07K14/505 , C12N5/071 , C12N5/074 , C12N15/117 , C12N15/67 , C12N15/85 , C12Q1/68
CPC分类号： A61K48/0066 , A61K38/177 , A61K38/1816 , A61K38/50 , A61K48/0041 , A61K48/005 , A61K48/0075 , C07H21/02 , C07K14/47 , C07K14/4712 , C07K14/505 , C12N5/0602 , C12N5/0696 , C12N15/117 , C12N15/67 , C12N15/85 , C12Q1/68 , C12Y305/04004 , A61K48/00 , C12N2310/17 , C12N2310/33 , C12N2310/3341 , C12N2501/40 , C12N2800/95
摘要： This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
-
公开(公告)号：US11905514B2
公开(公告)日：2024-02-20
申请号：US18080164
申请日：2022-12-13
发明人： Andrew Geall
IPC分类号： C12N15/117 , C12N15/86 , A61K39/155 , A61K39/39 , A61K39/12 , A61P31/12 , A61P37/04 , A61K48/00 , A61K39/00
CPC分类号： C12N15/117 , A61K39/12 , A61K39/155 , A61K39/39 , A61K48/0041 , A61K48/0083 , A61P31/12 , A61P37/04 , C12N15/86 , A61K2039/53 , A61K2039/552 , A61K2039/55555 , A61K2039/55566 , C12N2760/18534 , C12N2770/36143 , C12N2820/60
摘要： RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
-
8.发明授权公开(公告)号：US11898147B2
公开(公告)日：2024-02-13
申请号：US17467390
申请日：2021-09-06
IPC分类号： C07H21/02 , C12N15/117 , C07K16/28 , A61P35/00 , A61K31/711
CPC分类号： C12N15/117 , A61K31/711 , A61P35/00 , C07K16/2818 , C07K16/2827
摘要： The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.
-
公开(公告)号：US11891608B2
公开(公告)日：2024-02-06
申请号：US18080150
申请日：2022-12-13
发明人： Andrew Geall
IPC分类号： C12N15/117 , C12N15/86 , A61K39/155 , A61K39/39 , A61K39/12 , A61P31/12 , A61P37/04 , A61K48/00 , A61K39/00
CPC分类号： C12N15/117 , A61K39/12 , A61K39/155 , A61K39/39 , A61K48/0041 , A61K48/0083 , A61P31/12 , A61P37/04 , C12N15/86 , A61K2039/53 , A61K2039/552 , A61K2039/55555 , A61K2039/55566 , C12N2760/18534 , C12N2770/36143 , C12N2820/60
摘要： RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
-
公开(公告)号：US20240033348A1
公开(公告)日：2024-02-01
申请号：US18484667
申请日：2023-10-11
申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM , PULMOTECT, INC. , THE TEXAS A&M UNIVERSITY SYSTEM
发明人： Burton F. DICKEY , Michael J. TUVIM , Scott E. EVANS , Magnus HOOK , David P. HUSTON , Margarita MARTINEZ-MOCZYGEMBA , Brenton SCOTT
IPC分类号： A61K39/35 , A61P37/08 , A61K31/58 , A61K38/16 , C12N15/117 , H04B1/04 , H04B1/16 , H04B1/715 , H04B1/7156 , H04B1/40 , H04B1/713
CPC分类号： A61K39/35 , A61P37/08 , A61K31/58 , A61K38/164 , C12N15/117 , H04B1/04 , H04B1/16 , H04B1/715 , H04B1/7156 , H04B1/40 , H04B1/713 , A61K2039/55561
摘要： Certain embodiments are directed to compositions and methods for attenuating allergic responses in a subject.
-
-
-
-
-
-
-
-
-
搜索结果
601 条记录 (耗时 0.023 秒)
